english.prescrire.org > Topics > Advancing healthcare policy > The INN, a drug's real name > Prescrire's responses to INN consultations

Advancing healthcare policy

The INN, a drug's real name

Prescrire's responses to the WHO's consultations on proposed INNs

INNSince 2007, Prescrire has been participating in the public consultations on the INNs proposed by the WHO, by submitting comments intended to improve the safety of INNs.  
Français


The World Health Organization (WHO) releases for public consultation the international nonproprietary names (INNs) it proposes for drugs before their final adoption. Prescrire has been participating in these public consultations on proposed INNs since 2007, during which time it has submitted numerous comments. The WHO INN programme has occasionally taken certain objections into account.

It is easier to replace a proposed INN when a risk of confusion is identified early, before the drug concerned is brought to the market. Critical analysis of proposed INNs during WHO public consultations offers an insight into the challenges involved in devising common stems. It is useful for helping to make INNs safer.

LISTS OF PROPOSED INNs
 DOWNLOAD PRESCRIRE'S RESPONSE
 EXAMPLES OF CHANGES MADE
> List 126 (2022)
 In progress  
> List 126 - Covid-19 (2022)
 > Prescrire's Response 
(126 - Covid-19) (In French)		  
> List 125 (2021)
 > Prescrire's Response (125)  
> List 125 - Covid-19 (2021)
 > Prescrire's Response 
(125 - Covid-19) (In French)		  
> List 124 (2021)
 > Prescrire's Response (124)  
> List 124 - Covid-19 (2020)
 > Prescrire's Response (124 - Covid-19)  
> List 123 (2020)
 > Prescrire's Response (123) • valiloxibic acid (replaced by valiloxybate in list 124)
• pavunalimab (replaced by bavunalimab in list 125)
> List 122 (2020)
 > Prescrire's Response (122) • icatolimab (replaced by tifcemalimab in list 124)
• rulabricine alfa (replaced by ledelabricin alfa in list 124)
> List 121 (2019)
 > Prescrire's Response (121) • mavezelimab (replaced by favezelimab in list 123)
> List 120 (2019)
 > Prescrire's Response (120) • nidanilimab (replaced by nadunolimab in list 122)
> List 119 (2018)
 > Prescrire's Response (119) • setogepram (replaced by fezagepras in list 121)
• talditercept alfa (replaced by taldefgrobep alfa in list 121)
> List 118 (2018)
 > Prescrire's Response (118) • abeprazan (replaced by fexuprazan in list 120)
• diroleuton (replaced by daleuton in list 123)
• nedisertib (replaced by peposertib in list 120)
• nemorexant (replaced by daridorexant in list 120)
• vanalimab (replaced by mitazalimab in list 119)
> List 117 (2017)
 > Prescrire's Response (117) • adavivint (replaced by lorecivivint in list 119)
• loxicodegol (replaced by oxycodegol in list 119)
• renapersen (replaced by renadirsen in list 120)
• votrisiran (replaced by vutrisiran in list 119)
> List 116 (2017)
 > Prescrire's Response (116) • tavolixizumab (replaced by tavolimab in list 118)
> List 115 (2016)
 > Prescrire's Response (115)  
> List 114 (2015)
 > Prescrire's Response (114) • lendalizumab (replaced by olendalizumab in list 116)
• nalbuphine sebacate (replaced by dinalbuphine sebacate in list 116)
• pogalizumab (replaced by vonlerolizumab in list 116)
• raxatrigine (replaced by vixotrigine in list 116)
• sapélizumab (replaced by satralizumab in list 116)
> List 113 (2015)
 > Prescrire's Response (113) • fibatuzumab (replaced by ifabotuzumab in list 115)
> List 112 (2014)
 > Prescrire's Response (112) • asinercept (replaced by asunercept in list 114)
• erlosiban (replaced by nolasiban in list 114)
• ibiglustat (replaced by venglustat in list 114)
• lopixibat chloride (replaced by maralixibat chloride in list 113)
• neladenoson dalanate (replaced by neladenoson bialanate in list 113)
> List 111 (2014) > Prescrire's Response (111)  • irbinitinib (replaced by tucatinib in list 113)
> List 110 (2013) > Prescrire's Response (110) • veruprevir (replaced by paritaprevir in list 111)
> List 109 (2013) > Prescrire's Response (109) • velcalcetide (replaced by etelcalcetide in list 112)
> List 108 (2012) > Prescrire's Response (108)  
> List 107 (2012) > Prescrire's Response (107) • duligotumab (replaced by duligotuzumab in list 110)
• neceprevir (replaced by deldeprevir in list 110)
• saridegib (replaced by patidegib in list 111)
> List 106 (2011) > Prescrire's Response (106)  
> List 105 (2011) > Prescrire's Response (105)  
> List 104 (2010) > Prescrire's Response (104) • ronomilast (replaced by elbimilast in list 107)
> List 103 (2010) > Prescrire's Response (103) • tasocitinib (replaced by tofacitinib in list 105)
> List 102 (2009) > Prescrire's Response (102) • intedanib (replaced by nintedanib in list 105)
> List 101 (2009) > Prescrire's Response (101)  
> List 100 (2008) > Prescrire's Response (100)  
> List 99 (2008) > Prescrire's Response (99) • inolitazone (replaced by efatutazone in list 102)
> List 98 (2007) > Prescrire's Response (98)
• quarfloxine (replaced by itarnafloxine in list 103)
> List 97 (2007) > Prescrire's Response (97)  


©Prescrire March 2022